The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2024 | PanaMa: comparing maintenance and non-maintenance strategies in CRC
Dominik Paul Modest, MD, Charité – Universitätsmedizin Berlin, Berlin, Germany, discusses the potential biological mechanisms in colorectal cancer (CRC) behind the difference in progression free survival (PFS) at re-induction between the maintenance and non-maintenance arms of the PanaMa trial (NCT01991873). Continuing panitumumab, an anti-epidermal growth factor receptor (EGFR) antibody, may promote the development of resistant clones into a resistant tumor, which may render re-induction therapy less effective. Prof. Modest highlights that this would need to be biologically proven using biopsies. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Honoraria – Amgen; AstraZeneca/MedImmune; Bristol-Myers Squibb; Incyte; Lilly; Merck Serono; Merck Sharp & Dohme; Onkowissen; Pierre Fabre; Sanofi; SERVIER; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role – Amgen; Bristol-Myers Squibb; Cor2Ed; Incyte; IQvia; Lilly; Merck Serono; Merck Sharp & Dohme; Onkowissen; Pierre Fabre; Roche; SERVIER
Research Funding – Amgen (Inst); Servier (Inst)
Travel, Accommodations, Expenses – Amgen; Merck Serono; SERVIER
